{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:07:41Z","timestamp":1790222861993,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jval.2017.01.015","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:22:03Z","timestamp":1487870523000},"page":"736-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations"],"prefix":"10.1016","volume":"20","author":[{"given":"Gigi A.","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"S\u00e1nchez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"D\u00edaz Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana K.","family":"Vania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Edlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Brookmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2017.01.015_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2017.01.015_bib2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/lt.23551","article-title":"Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma","volume":"18","author":"Biggins","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jval.2017.01.015_bib3","year":"2015","journal-title":"Hepatitis C information for health professionals"},{"key":"10.1016\/j.jval.2017.01.015_bib4","unstructured":"National Health and Nutrition Examination Survey Data [Waves 2003-2004 through 2011-2012]. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2010. Available from: https:\/\/www.cdc.gov\/nchs\/nhanes\/. [Accessed November 1, 2015]."},{"key":"10.1016\/j.jval.2017.01.015_bib5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2017.01.015_bib6","doi-asserted-by":"crossref","first-page":"e101554","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","volume":"9","author":"Yehia","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jval.2017.01.015_bib7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep.25556","article-title":"Awareness of infection, knowledge of hepatitis C, and medical follow\u2010up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001\u20132008","volume":"55","author":"Denniston","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2017.01.015_bib8","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jval.2017.01.015_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jhep.2013.11.009","article-title":"Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients","volume":"60","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jval.2017.01.015_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","article-title":"Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006","volume":"171","author":"Williams","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2017.01.015_bib11","first-page":"57","article-title":"Surveillance for Acute Viral Hepatitis, United States, 2006","author":"Wasley","year":"2008","journal-title":"Department of Health and Human Services, Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jval.2017.01.015_bib12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jval.2017.01.015_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5694\/j.1326-5377.1999.tb140325.x","article-title":"The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not","volume":"170","author":"Crofts","year":"1999","journal-title":"Med J Australia"},{"key":"10.1016\/j.jval.2017.01.015_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/QCO.0b013e32835c2120","article-title":"Sexually transmitted hepatitis C infection: the new epidemic in MSM?","volume":"26","author":"Bradshaw","year":"2013","journal-title":"Curr Opinion Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/sextrans-2012-050566","article-title":"Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review","volume":"88","author":"Yaphe","year":"2012","journal-title":"Sexually Transmitted Infect"},{"key":"10.1016\/j.jval.2017.01.015_bib17","unstructured":"Centers for Disease Control and Prevention. HIV and viral hepatitis. 2014. Available from: http:\/\/www.cdc.gov\/hiv\/pdf\/library_factsheets_hiv_and_viral_hepatitis.pdf. [September 1, 2016]."},{"key":"10.1016\/j.jval.2017.01.015_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/cid\/ciq201","article-title":"Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials","volume":"52","author":"Taylor","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new hepatitis C virus treatment under state Medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2017.01.015_bib20","year":"2015","journal-title":"Medication quantity limit Sovaldi"},{"key":"10.1016\/j.jval.2017.01.015_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2017.01.015_bib22","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1377\/hlthaff.2014.1193","article-title":"Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern","volume":"34","author":"Van Nuys","year":"2015","journal-title":"Health Aff"},{"key":"10.1016\/j.jval.2017.01.015_bib23","first-page":"SP227","article-title":"Value of expanding HCV screening and treatment policies in the United States","volume":"22","author":"Linthicum","year":"2016","journal-title":"Am J Managed Care"},{"key":"10.1016\/j.jval.2017.01.015_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/cid\/cit197","article-title":"Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984\u20132011","volume":"57","author":"Witt","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib25","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jval.2017.01.015_bib26","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.23399","article-title":"Distribution of hepatitis C virus genotypes in a diverse US integrated health care population","volume":"84","author":"Manos","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.jval.2017.01.015_bib27","year":"2014","journal-title":"UnitedHealthcare Pharmacy, Clinical Pharmacy Programs, Prior Authorization\/Medical Necessity Harvoni\u2122 (ledipasvir\/sofosbuvir)"},{"key":"10.1016\/j.jval.2017.01.015_bib28","author":"Aetna","year":"2015","journal-title":"Pharmacy clinical policy bulletins, Aetna non-Medicare prescription drug plan: hepatitis C"},{"key":"10.1016\/j.jval.2017.01.015_bib29","author":"Anthem","year":"2015","journal-title":"Viekira Pak (ombitasvir\/paritaprevir\/ritonavir + dasabuvir)"},{"key":"10.1016\/j.jval.2017.01.015_bib30","author":"Health","year":"2015","journal-title":"Prior authorization protocol: SOLVALDI\u2122 (sofosbuvir)"},{"key":"10.1016\/j.jval.2017.01.015_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new hepatitis C virus treatment under state Medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2017.01.015_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2017.01.015_bib33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2017.01.015_bib34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","article-title":"HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage","volume":"375","author":"Mathers","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jval.2017.01.015_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/10826080600669579","article-title":"Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence","volume":"41","author":"Wodak","year":"2006","journal-title":"Substance Use Misuse"},{"key":"10.1016\/j.jval.2017.01.015_bib36","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/474S18a","article-title":"Perspective: test and treat this silent killer","volume":"474","author":"Edlin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jval.2017.01.015_bib37","unstructured":"Health Canada. Vancouver\u2019s INSITE service and other supervised injection sites: what has been learned from research? Health Canada, March 31, 2008. Available from: http:\/\/www.hc-sc.gc.ca\/ahc-asc\/pubs\/_sites-lieux\/insite\/index-eng.php. [Accessed September 1, 2016]."},{"issue":"Suppl 2","key":"10.1016\/j.jval.2017.01.015_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/00333549071220S211","article-title":"The costs and impacts of testing for hepatitis C virus antibody in public STD clinics","volume":"122","author":"Honeycutt","year":"2007","journal-title":"Public Health Rep"},{"issue":"2","key":"10.1016\/j.jval.2017.01.015_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF03405777","article-title":"My place, your place, or a safer place: the intention among Montreal injecting drug users to use supervised injecting facilities","volume":"95","author":"Green","year":"2004","journal-title":"Can J Public Health"},{"key":"10.1016\/j.jval.2017.01.015_bib40","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1503\/cmaj.060863","article-title":"Summary of findings from the evaluation of a pilot medically supervised safer injecting facility","volume":"175","author":"Wood","year":"2006","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jval.2017.01.015_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2017.01.015_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jval.2017.01.015_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jgh.12041","article-title":"Assessing the cost\u2010effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia","volume":"28","author":"Visconti","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2017.01.015_bib44","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edlin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/cid\/cit306","article-title":"Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep.27766","article-title":"Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause\u2010specific outcomes","volume":"62","author":"Innes","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2017.01.015_bib48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.annepidem.2014.01.008","article-title":"Do metropolitan HIV epidemic histories and programs for people who inject drugs and men who have sex with men predict AIDS incidence and mortality among heterosexuals?","volume":"24","author":"Friedman","year":"2014","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jval.2017.01.015_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/10826084.2011.521473","article-title":"HIV heterosexual sexual risk from injecting drug users among HIV-seronegative noninjecting heroin users","volume":"46","author":"Neaigus","year":"2011","journal-title":"Substance Use Misuse"},{"key":"10.1016\/j.jval.2017.01.015_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11904-010-0043-7","article-title":"Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions","volume":"7","author":"Strathdee","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.jval.2017.01.015_bib51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.epidem.2010.06.003","article-title":"Epidemiological bridging by injection drug use drives an early HIV epidemic","volume":"2","author":"Volz","year":"2010","journal-title":"Epidemics"},{"key":"10.1016\/j.jval.2017.01.015_bib52","author":"AASLD\/IDSA","year":"2016","journal-title":"HCV guidance: recommendations for testing, managing, and treating HCV"},{"key":"10.1016\/j.jval.2017.01.015_bib53","series-title":"Guidelines for the Screening Care and Treatment of Persons With Hepatitis C Infection","year":"2014"},{"key":"10.1016\/j.jval.2017.01.015_bib54","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2017.01.015_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/apt.13673","article-title":"Review article: treatment as prevention\u2013targeting people who inject drugs as a pathway towards hepatitis C eradication","volume":"44","author":"Leask","year":"2016","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.jval.2017.01.015_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2017.01.015_bib57","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.26623","article-title":"Eradication of hepatitis C infection: the importance of targeting people who inject drugs","volume":"59","author":"Hellard","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2017.01.015_bib58","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.drugpo.2015.05.006","article-title":"Hepatitis C transmission and treatment as prevention\u2013the role of the injecting network","volume":"26","author":"Hellard","year":"2015","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jval.2017.01.015_bib59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tim.2013.09.008","article-title":"Treatment as prevention and cure towards global eradication of hepatitis C virus","volume":"21","author":"Hagan","year":"2013","journal-title":"Trends Microbiol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517300852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517300852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T17:30:31Z","timestamp":1658683831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301517300852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1098301517300852"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2017.01.015","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2017.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}